Vedolizumab is a humanized monoclonal antibody designed to selectively inhibit the alpha4beta7 integrin. It is used in research to study mechanisms and therapeutic strategies for inflammatory bowel diseases, including in vitro adhesion assays and in vivo models of Crohns disease and ulcerative colitis.
Konzentration:
4.89 mg/mL
Molekulargewicht:
146.80 kDa
Reinheit:
99.10% (May vary between batches)
CAS Nummer:
[943609-66-3]
Target-Kategorie:
Integrin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten